Literature DB >> 12591819

Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator.

H Solomon1, J W Man, G Jackson.   

Abstract

Erectile dysfunction (ED) is a common condition and studies predict that it will become even more common in the future. There is increasing evidence to suggest that it is predominantly a vascular disease and may even be a marker for occult cardiovascular disease. The common pathological process is at the level of the endothelium, and cardiovascular risk factor control may be the key to preventing ED. Many men with established cardiovascular disease have ED. Specific guidelines for the management of ED in these patients have been produced by an expert panel. Cardiovascular risk stratification is an important initial step in managing such patients. In cardiac patients considered to have low cardiovascular risk, the management of ED can be safe and effective.

Entities:  

Mesh:

Year:  2003        PMID: 12591819      PMCID: PMC1767600          DOI: 10.1136/heart.89.3.251

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  21 in total

Review 1.  Sexual activity as a trigger for cardiovascular events: what is the risk?

Authors:  J E Muller
Journal:  Am J Cardiol       Date:  1999-09-09       Impact factor: 2.778

Review 2.  Erectile dysfunction.

Authors:  T F Lue
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

3.  Sexual Activity and Cardiac Risk: The Princeton Conference. New Jersey, USA, June 1999.

Authors: 
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

4.  Does severity of ischemic coronary disease correlate with erectile function?

Authors:  A Greenstein; J Chen; H Miller; H Matzkin; Y Villa; Z Braf
Journal:  Int J Impot Res       Date:  1997-09       Impact factor: 2.896

5.  Quality of life effects of alprostadil therapy for erectile dysfunction.

Authors:  R J Willke; H A Glick; T J McCarron; M H Erder; S E Althof; O I Linet
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

Review 6.  The epidemiology of erectile dysfunction and its risk factors.

Authors:  A Bortolotti; F Parazzini; E Colli; M Landoni
Journal:  Int J Androl       Date:  1997-12

Review 7.  Sexual intercourse and stable angina pectoris.

Authors:  G Jackson
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

Review 8.  Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

Authors:  R DeBusk; Y Drory; I Goldstein; G Jackson; S Kaul; S E Kimmel; J B Kostis; R A Kloner; M Lakin; C M Meston; M Mittleman; J E Muller; H Padma-Nathan; R C Rosen; R A Stein; R Zusman
Journal:  Am J Cardiol       Date:  2000-07-15       Impact factor: 2.778

Review 9.  Erectile dysfunction, sildenafil and cardiovascular risk.

Authors:  K K Chew; B G Stuckey; P L Thompson
Journal:  Med J Aust       Date:  2000-03-20       Impact factor: 7.738

Review 10.  Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  Circulation       Date:  1999 Jan 5-12       Impact factor: 29.690

View more
  67 in total

1.  Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.

Authors:  Catherine Do; Eric Huyghe; Maryse Lapeyre-Mestre; Jean Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats.

Authors:  Xue-Feng Qiu; Xiao-Xin Li; Yun Chen; Hao-Cheng Lin; Wen Yu; Run Wang; Yu-Tian Dai
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  Hypovitaminosis D is associated with erectile dysfunction in type 2 diabetes.

Authors:  Nicola Caretta; Saula Vigili de Kreutzenberg; Umberto Valente; Gabriella Guarneri; Alberto Ferlin; Angelo Avogaro; Carlo Foresta
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

4.  Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

Authors:  Dean Patterson; Gordon T McInnes; John Webster; Malcolm M Mitchell; Thomas M Macdonald
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 5.  Erectile dysfunction and risk of cardiovascular and all-cause mortality in the general population: a meta-analysis of cohort studies.

Authors:  Yu Fan; Binbin Hu; Changfeng Man; Feilun Cui
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

6.  Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing.

Authors:  Stacy Tessler Lindau; Natalia Gavrilova
Journal:  BMJ       Date:  2010-03-09

7.  Correlation between penile cavernosal artery blood flow and retinal vascular findings in arteriogenic erectile dysfunction.

Authors:  Ahmed M Emarah; Shawky M El-Haggar; Ihab A Osman; Abdel Wahab S Khafagy
Journal:  Clin Ophthalmol       Date:  2010-09-20

8.  Association between body size and composition and erectile dysfunction in older men: Osteoporotic Fractures in Men Study.

Authors:  Pranav S Garimella; Misti L Paudel; Kristine E Ensrud; Lynn M Marshall; Brent C Taylor; Howard A Fink
Journal:  J Am Geriatr Soc       Date:  2013-01       Impact factor: 5.562

Review 9.  Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Authors:  Yoram Vardi
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.